---

COPD Management

1. Diagnosis & Classification

---

2. Non-Pharmacological Management

Smoking Cessation

Pulmonary Rehabilitation

• Indicated for dyspnea at rest or on minimal exertion (mMRC ≥ 2), GOLD 2–4
• Reduces dyspnea, improves exercise tolerance and quality of life
• Combines aerobic training, resistance exercise, and education
• Effects persist up to 12 months; repeated courses are beneficial

Vaccination

• Annual influenza vaccine (reduces exacerbations and mortality)
• Pneumococcal vaccine (PCV15/PCV20 preferred)
• COVID-19 and RSV vaccines per current schedules

Nutrition

• Underweight patients (BMI ≤ 21) have higher mortality; nutritional support is indicated
• Obesity can worsen dyspnea; weight optimization is beneficial

Exercise & Physical Activity

• Even light physical activity reduces hospitalization and mortality
• Encourage walking programs alongside rehabilitation

---

3. Pharmacotherapy (Stable COPD)

Short-Acting Bronchodilators (SABDs) — Rescue

Long-Acting Bronchodilators (LABDs) — Maintenance

Inhaled Corticosteroids (ICS)

• Reduce exacerbation rate by ~15–20% (relative)
• Do not reduce the rate of FEV1 decline or mortality as monotherapy
• Always combine with a LABA; never use ICS alone in COPD
• Greater benefit when blood eosinophils ≥ 300 cells/μL
• Key side effects: oropharyngeal candidiasis, dysphonia, increased pneumonia risk — weigh carefully

Escalation Strategy

• Umeclidinium 62.5 μg + vilanterol 25 μg + fluticasone furoate 100 μg (once daily)
• Glycopyrrolate 18 μg + formoterol 9.6 μg + budesonide 160/320 μg (twice daily)

PDE4 Inhibitors

• Roflumilast 500 μg orally once daily
• Indicated for: severe COPD (FEV1 < 50%), chronic bronchitis phenotype, ≥2 exacerbations/year despite ICS + LABA + LAMA
• Increases FEV1 ~50 mL; reduces exacerbations and hospitalizations
• Side effects: nausea, diarrhea, weight loss (useful in obese patients), psychiatric effects

Macrolide Prophylaxis

• Azithromycin 250 mg every other day (or 250 mg daily) — reduces exacerbation frequency
• Reserved for patients with ≥2 exacerbations/year on maximal inhaled therapy
• Screen for: hearing loss, prolonged QTc, non-tuberculous mycobacteria (sputum culture first)

Methylxanthines

• Theophylline — modest bronchodilation; largely superseded by LABDs
• Narrow therapeutic window; interactions and toxicity limit use
• Consider only when inhaled therapy is unavailable or not tolerated

---

4. Oxygen Therapy & Ventilatory Support

Long-Term Oxygen Therapy (LTOT)

• Indicated when resting SaO₂ ≤ 88% (or PaO₂ < 56 mmHg)
• Target: SaO₂ consistently > 90% at rest
• 24 h/day use reduces mortality, polycythemia, and pulmonary hypertension
• Note: Oxygen for moderate resting hypoxemia (SaO₂ 88–93%) or exercise-induced desaturation alone does not reduce mortality or hospitalization

Non-Invasive Ventilation (NIV)

• Home nocturnal NIV added to LTOT reduces hospitalizations and delays mortality in patients with persistent hypercapnia (PaCO₂ > 52 mmHg after a stabilized exacerbation)
• High-flow nasal cannula is an alternative in some patients

---

5. Surgical & Bronchoscopic Interventions

Lung Volume Reduction Surgery (LVRS)

• Reduces hyperinflation by resection of emphysematous tissue (typically via VATS)
• Best candidates: upper-lobe-predominant emphysema + low exercise capacity
• Improves FEV1, quality of life, and reduces mortality in selected patients
• Contraindicated: FEV1 < 20% predicted + DLCO < 20% (high perioperative mortality)

Bronchoscopic Lung Volume Reduction

• Endobronchial one-way valves, coils, or transbronchial stents
• Most effective in heterogeneous emphysema with intact interlobar fissures and no collateral ventilation
• Provides modest improvement in FEV1 and quality of life

Lung Transplantation

• Indicated for end-stage COPD not amenable to other interventions
• Bilateral transplant now preferred (~75% of cases) — better long-term survival than single lung
• COPD accounts for ~25% of all US lung transplants; median survival 5.8 years

---

6. Management of Acute Exacerbations (AECOPD)

• Short-term mortality ~10%; responsible for ~60% of direct COPD costs
• Pathogens implicated in 75–80% of cases (viruses > bacteria)

Assessment

• Vitals, SpO₂, ABG (if distress or suspected hypercarbia)
• CXR (to exclude pneumonia, pneumothorax, heart failure)
• BNP if left heart failure suspected
• Consider CT-PA if pulmonary embolism is likely

Indications for Hospitalization

• Hypercarbia or acidemia
• Significant respiratory distress despite initial bronchodilator therapy
• Inability to manage at home (poor social support, functional decline, confusion)

Treatment

• Standard: Azithromycin 500 mg/day × 5 days or amoxicillin-clavulanate 875/125 mg BD × 5 days
• Pseudomonas risk (severe COPD, prior hospitalization, prior colonization): Levofloxacin 750 mg/day × 7–10 days
• Organisms covered: S. pneumoniae, H. influenzae, M. catarrhalis

Post-Exacerbation Care

• Optimize inhaled therapy before discharge (step up if needed)
• Pulmonary rehabilitation referral within 4 weeks
• Follow-up within 4 weeks of discharge
• Consider prophylactic azithromycin for recurrent exacerbators

---

7. Comorbidity Management

• Cardiovascular disease (most common cause of death in mild–moderate COPD): beta-blockers are not contraindicated and are beneficial
• Depression/anxiety: screen with PHQ-9; treat actively
• Osteoporosis: ICS use increases risk; DEXA screening; supplement Ca²⁺ + Vitamin D
• Lung cancer: low-dose CT screening annually (if ≥20 pack-year history, age 50–80)
• Sleep apnea (overlap syndrome): treat with CPAP to improve outcomes

---

Summary: Stable COPD Treatment Algorithm

Confirmed COPD (FEV1/FVC < 0.70)
         ↓
Smoking cessation + vaccination + rehab (all stages)
         ↓
Symptoms + spirometry + exacerbation history
         ↓
SABA PRN (mild, infrequent) 
         ↓
LAMA monotherapy (first-line maintenance)
         ↓
Add LABA (if persistent symptoms) → Dual bronchodilation (LAMA + LABA)
         ↓
Add ICS (if eos ≥100 + ≥1 severe or ≥2 moderate exacerbations) → Triple therapy
         ↓
Add roflumilast and/or azithromycin (if FEV1 <50% + chronic bronchitis + frequent exacerbations)
         ↓
Consider LVRS / bronchoscopic LVR / transplant (advanced disease)

---

• Goldman-Cecil Medicine, International Edition (Vol. 2) — Chapter 76: COPD
• Fishman's Pulmonary Diseases and Disorders (2-Volume Set) — Chapter 40: Course and Treatment of COPD
• Katzung's Basic and Clinical Pharmacology, 16th Edition — Chapter: Treatment of COPD